Insilico Medicine Reports Phase 2a Proteomic Analysis Demonstrating Biological Age Reversal for IPF Candidate Rentosertib

A multi-clock proteomic analysis of Insilico Medicine's Phase 2a clinical data for its idiopathic pulmonary fibrosis candidate, rentosertib, showed a reduction in predicted biological age of up to six years, establishing a clinical blueprint for dual-purpose therapeutics.

Using 12-week longitudinal Olink proteomic data across 2,841 proteins from 42 idiopathic pulmonary fibrosis (IPF) patients in a Phase 2a trial, researchers evaluated biological age using six independently developed proteomic aging clocks.

All six models—including ProtAge, OrganAge, and PAC—consistently showed a reduction in predicted biological age, peaking at Week 4 in the 30 mg BID cohort with a 3-to-4-year reduction and up to 6 years in a specific clock.

Rentosertib, a small molecule designed by generative AI to target TNIK, demonstrated senomorphic activity by suppressing cellular senescence drivers (including EREG, ESM1, and MMP10) and downregulating aging-associated RTK-PI3K and RAS-ERK growth-factor signaling pathways.

This represents the first clinical evaluation of a de-novo AI-designed molecule targeting an AI-discovered, dual-purpose target to demonstrate biological age reversal, moving beyond traditional geroscience approaches reliant on repurposed generic drugs.

The study presents a scalable blueprint for embedding geroscience endpoints into disease-focused trials, outlining a path for biomarker qualification and composite clinical endpoints under the FDA Biomarker Qualification Program and FDA-NIH BEST framework.

The observed systemic age-reversal signal operated partially independent of pulmonary function improvements (Forced Vital Capacity), indicating the drug's geroprotective effects are not merely a secondary downstream consequence of localized disease resolution.

The findings support the commercial viability of dual-purpose target discovery platforms, validating that drug candidates can simultaneously address acute disease indications and systemic aging hallmarks.

The alignment across six independent proteomic clocks, despite differing methodologies and training targets, reduces model-specific risk and bolsters the credibility of using proteomic aging clocks in clinical development.

Insilico's commercial performance, including $106 million in H1 2026 revenue and achieving profitability, indicates that dual-purpose pipelines can sustain traditional biotechnology business models while targeting longevity endpoints.

The progression of rentosertib's Phase 3 clinical trial evaluating idiopathic pulmonary fibrosis (IPF) in China.

Potential future trials evaluating rentosertib or other dual-purpose candidates in healthy volunteers to isolate direct biological aging effects from disease-treatment variables.